Keywords
COVID-19
Pandemic
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To investigate coagulation disorders and their impacts on patients infected with SARS-CoV-2. Bibliographic review: Betacoronavirus, characterized by high contagiousness, being recognized by the World Health Organization as a public health problem. The infection can cause significant health impacts, including coagulation disorders and severe thrombotic events. Literature findings indicate that SARS-CoV-2 can cause vascular damage through direct cytotoxic immune response and inhibition of the angiotensin-converting enzyme II, favoring the activation of the coagulation cascade via tissue factor and the development of thromboses. Furthermore, elevated levels of D-dimer, a product of fibrin degradation, are associated with coagulopathies in COVID-19 patients. Final considerations: Although there is still no consensus on the exact pathogenicity of these complications, it is known that the increase of PAI-1, thromboxane A2 and fibrinogen are associated with the immunothrombotic state of the infection. Therefore, new studies are needed to consolidate this association and guide effective therapeutic strategies.
References
ARAÚJO IG, MORAIS ACLN. Fenômeno da hipercoagulabilidade em pacientes com COVID-19. InterAmerican Journal of Medicine and Health, 2020; 3: 1-9.
AYANIAN S, et al. The association between biomarkers and clinical outcomes in novel coronavirus pneumonia in a US cochrt. Biomarkers in Medicine, 2020; 14(12): 1091-1097.
BATSCHAUER APB, JOVITA HW. Hemostasia e COVID-19: fisiopatologia, exames laboratoriais e terapia anticoagulante. A Tempestade do Coronavírus, 2020; 52(2): 138-42.
BENVENUTO D, et al. The 2019‐new coronavirus epidemic: evidence for virus evolution. Journal of medical virology, 2020; 92(4): 455-459.
BAHIA DSLN, et al. Distúrbios da coagulação em pacientes obstétricas infectadas pelo SARS-CoV-2 (COVID-19). Revista Eletrônica Acervo Científico, 2021; 25: e7077.
DESAI AD, et al. Long-term complications of COVID-19. Am J Physiol Cell Physiol, 2022; 322(1):C1-C11.
FIORI CFR, FRIZZO MN. Hemostasia e sua relação com o quadro clínico e laboratorial em pacientes com covid-19: uma revisão bibliográfica. Salão do Conhecimento, 2021; 7(7).
HOECHTER DJ, et al. Higher procoagulatory potential but lower DIC score in COVID-19 ARDS patientes compared to non-COVID-19 ARDS patientes. Thrombosis Research, 2020; 196: 186-192.
JIN X, et al. The values of coagulation function in COVID-19 patients. Plos One, 2020; 15(10).
LEPPKES M, et al. Vascular occlusion byneutrophil extracellular traps in COVID-19. Ebiomedicine, 2020; 58: 102925.
LIMA JMN, et al. Alteração da coagulação e covid-19: uma associação entre aspectos epidemiológicos e laboratoriais para o monitoramento da covid-19. 2021.
MEDICINANET, Distúrbio da coagulação. https://www.medicinanet.com.br/conteudos/acp-medicine/5864/disturbios_da_coagulacao.htm/> Acesso em: 05 de mar. de 2026.
MURTA MS. Hipercoagulabilidade na COVID-19: Prevenção, Diagnóstico e Tratamento. Pulmão RJ, 2020; 29(1): 17-21.
ORSI FLA, GUERRA JCC. Hypercoagulability, thromboembolic events and anticoagulation in COVID-19. Rev Soc Cardiol Estado de São Paulo, 2020, 30(4):462-71.
ORSINI MA, et al. Coagulação intravascular disseminada e covid-19: mecanismos fisiopatológicos. Revista De Saúde, 2020, 11(1): 87-90.
PIERINI S, et al. La coagulopatia nel COVID-19: basi fisiopatologiche. Giornale Italiano di Cardiologia, 2020; 21(7): 483-488.
POMPERMAIER C, et al. Análise das principais coagulopatias que acometem os pacientes com covid-19: uma revisão integrativa. Anuário Pesquisa e Extensão Unoesc Xanxerê, 2021; 6: e28024-e28024.
ROBERTO GA, et al. COVID-19 e eventos tromboembólicos. Ulakes journal of medicine, 2020; 1.
SANTO BZ. Sars-Cov-2: um breve resumo sobre as alterações plaquetárias. 2020.
SMADJA DM, et al. Angiopoietin-2 as marker of endotelial activations is a good predictor fator intense care unit admission os COVID-19 patients. Angiogenesis, 2020; 23(4): 611-620.
UZUNIAN A. Coronavirus SARS-CoV-2 and Covid-19. J Bras Patol Med Lab, 2020; 56: 1-4.
WANG J, et al. Thrombo-inflammatory features predicting mortality in patients with COVID-19: The FAD-85 score. Journal of International Medical Research, 2020; 48(9).
XU J, et al. Clinical couser and predictores of 60-day mortality in 239 critically ill patients with COVID-19: a multicenter retrospective study from Wuhan, China. Critical Care, 2020; 24.